Guideline-Concordant Surveillance After Treatment for High-Grade Cervical Dysplasia
Approximately half of patients did not receive guideline-concordant surveillance after treatment for high-grade dysplasia, and one-third had a subsequent abnormal co-test result. Patients with high-grade cervical dysplasia are at elevated risk of subsequent abnormalities and should continue to be closely monitored. Additional systematic monitoring is needed to ensure guideline-compliant surveillance after dysplasia treatment.
Authors
- Sarah Feldman (ORCID: https://orcid.org/0000-0002-5582-9401)
- Jacquelyn M. Lykken (ORCID: https://orcid.org/0000-0003-0872-0873)
- Claudia L. Werner (ORCID: https://orcid.org/0000-0003-0457-5269)
- Victoria Wang (ORCID: https://orcid.org/0000-0001-6513-2889)
- Rebecca B. Perkins (ORCID: https://orcid.org/0000-0002-7054-3014)
- Sarah C. Kobrin (ORCID: https://orcid.org/0000-0002-1391-6048)
- Jasmin A. Tiro (ORCID: https://orcid.org/0000-0001-8300-0441)
- Jennifer S. Haas
Institutions
- Parkland Health & Hospital System (US)
Publication Details
- Journal
- Obstetrics and Gynecology
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1097/aog.0000000000005877
- Citations
- 3
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Division of Cancer Epidemiology and Genetics, National Cancer Institute